.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,977,066

« Back to Dashboard

Details for Patent: 5,977,066

Title: Cyclosporin galenic forms
Abstract:Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.
Inventor(s): Cavanak; Thomas (Biel-Benken, CH)
Assignee: Novartis AG (Basel, CH)
Filing Date:Mar 24, 1998
Application Number:09/047,056
Claims:1. A method of orally administering a pharmaceutical composition, said method comprising orally administering to a patient a composition comprising about 2.0 to about 20% by weight of cyclosporin A in a carrier medium comprising monoglycerides, diglycerides, triglycerides, and a reaction product of a natural or hydrogenated castor oil and ethylene oxide, and said cyclosporin A and said reaction product are present in a ratio of from about 1:0.1 to about 1:5 on a by weight basis, all weight percents being based on the total weight of the composition.

2. The method of claim 1, wherein said carrier medium further comprises ethanol.

3. The method of claim 1, wherein said carrier medium further comprises a transesterification product of a natural vegetable oil triglyceride and a polyalkylene polyol.

4. The method of claim 1, wherein said reaction product is a reaction product of a natural castor oil and ethylene oxide.

5. The method of claim 1, wherein said reaction product is a reaction product of a hydrogenated castor oil and ethylene oxide.

6. A method of orally administering a pharmaceutical composition, said method comprising orally administering to a patient a composition comprising about 2.0 to about 20% by weight of cyclosporin A in a carrier medium comprising monoglycerides, diglycerides, triglycerides, a reaction product of a natural or hydrogenated castor oil and ethylene oxide, and a transesterification product of a natural vegetable oil triglyceride and a polyalkylene polyol, and said cyclosporin A and said reaction product are present in a ratio of from about 1:0.1 to about 1:5 on a by weight basis, all weight percents being based on the total weight of the composition.

7. The method of claim 6, wherein said carrier medium further comprises ethanol.

8. The method of claim 6, wherein said reaction product is a reaction product of a natural castor oil and ethylene oxide.

9. The method of claim 6, wherein said reaction product is a reaction product of a hydrogenated castor oil and ethylene oxide.

10. A method of allowing dosaging of cyclosporin A at a controlled dosage rate, said method comprising orally administering to a patient a pharmaceutical composition comprising about 2.0 to about 20% by weight of cyclosporin A, based on the total weight of the composition, in a carrier medium comprising monoglycerides, diglycerides and triglycerides.

11. The method of claim 10, wherein said carrier medium further comprises a reaction product of a natural or hydrogenated castor oil and ethylene oxide.

12. The method of claim 10, wherein said carrier medium further comprises ethanol.

13. The method of claim 11, wherein said carrier medium further comprises a transesterification product of a natural vegetable oil triglyceride and a polyalkylene polyol.

14. The method of claim 11, wherein said reaction product is a reaction product of a natural castor oil and ethylene oxide.

15. The method of claim 11, wherein said reaction product is a reaction product of a hydrogenated castor oil and ethylene oxide.

16. A method of allowing dosaging of cyclosporin A at a controlled dosage rate, said method comprising orally administering to a patient a pharmaceutical composition comprising about 2.0 to about 20% by weight of cyclosporin A, based on the total weight of the composition, in a carrier medium comprising monoglycerides, diglycerides, triglycerides, and a reaction product of a natural or hydrogenated castor oil and ethylene oxide.

17. The method of claim 16, wherein said carrier medium further comprises a transesterification product of a natural vegetable oil triglyceride and a polyalkylene polyol.

18. The method of claim 16, wherein said carrier medium further comprises ethanol.

19. The method of claim 16, wherein said reaction product is a reaction product of a natural castor oil and ethylene oxide.

20. The method of claim 16, wherein said reaction product is a reaction product of a hydrogenated castor oil and ethylene oxide.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc